Sotagliflozin Shows Clot Reduction in Small Trial
Lexicon Pharmaceuticals presented new sotagliflozin data at the 2026 American Heart Association Scientific Sessions.
Updated on Nov. 9, 2026 in Heart Disease

Lexicon Pharmaceuticals announced new data on sotagliflozin at the 2026 American Heart Association Scientific Sessions. In a randomized crossover study of 15 healthy adults, sotagliflozin significantly reduced clot formation under both arterial-like and venous-like conditions.
Why it matters
The findings add early laboratory and small-study evidence on how sotagliflozin may affect blood clotting and heart muscle work in hypertrophic cardiomyopathy (HCM). The results are preliminary and come from a small, open-label study, so they do not establish clinical benefit.
The study enrolled 15 healthy adults in a 4-week randomized, open-label crossover trial comparing once-daily sotagliflozin 400 mg with empagliflozin 10 mg, with clot reductions of 11.9% and 15.6% for sotagliflozin under arterial-like and venous-like conditions. Whether these short-term laboratory effects translate to patients with hypertrophic cardiomyopathy has not been established.
The players
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas, that is developing sotagliflozin.
Ichan School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is a medical school in New York City that is part of the Mount Sinai Health System.
Penn Cardiovascular Institute
The Penn Cardiovascular Institute is a cardiovascular research and clinical program affiliated with the University of Pennsylvania.
The details
Researchers measured clot formation in participants' blood before and after each treatment using an ex vivo laboratory model, and separately studied myocardial work in living myocardial slices across a range of afterloads. Short-term exposure to sotagliflozin and empagliflozin directly reduced work performed by human heart muscle in HCM tissue, with sotagliflozin showing greater potency at higher afterloads. The findings were published simultaneously in JACC: Basic to Translational Science.
Timeline
November 9, 2026: Lexicon announced the new sotagliflozin data at the American Heart Association 2026 meeting.
First quarter 2027: Topline results from the Phase 3 SONATA-HCM trial are expected.
Big Picture
These early findings feed directly into the Phase 3 SONATA-HCM trial, which is testing sotagliflozin in symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy. Its topline results, expected in the first quarter of 2027, will determine whether the laboratory effects seen here carry over to patients.
For people living with hypertrophic cardiomyopathy, these findings do not yet change treatment, since the evidence comes from a small study in healthy adults and laboratory tissue. Patients and clinicians will need the larger Phase 3 results before any clinical implications can be drawn.
The takeaway
Laboratory and short-term studies can show promising mechanisms, but clinical benefit in hypertrophic cardiomyopathy will depend on the results of larger trials. Readers should watch for the SONATA-HCM topline data expected in early 2027.
What happens next
Topline results from the Phase 3 SONATA-HCM trial are expected in the first quarter of 2027.
Further reading
Explore more on Heart Disease for background on the condition at the center of this research.
Source note: This article includes information reported by The Manila times.






